SpineVision, a Antony (south of Paris), France-based medical device company that designs, develops and markets products for the surgical treatment of spine disorders, raised $10m in funding.
The round was led by new investor Omega Funds, with participation from existing investors.
The company intends to use the funds to expand existing commercial operations, primarily in the U.S. market, grow commercial activities in Europe, strengthen R&D efforts and develop an innovative approach to the traditional supply chain.
Founded in 1999 and by Arnaud Brisard, CEO, SpineVision is an integrated spinal technology company focused on developing and marketing implants and instrumentation for treatment of spinal pathologies including lumbar degenerative disc diseases, deformities, cervical disorders, trauma and tumors.
The company recently received CE marking for its new generation Flex+2(TM) dynamic stabilization rod. In addition 510(k) approval has been granted for a range of surgical instrumentation focused on a minimally invasive approach to treating conditions related to aging and degeneration of the spine.
SpineVision currently operates in France, Italy, Benelux, UK and the United States, and has distribution agreements in other territories, including in emerging markets.